Mahindra Group subsidiary, Mahindra Aerospace has been awarded a large aero-components production contract by Airbus Group company, Premium AEROTEC of Germany. The multi-year contract envisages the manufacture and supply by Mahindra of a variety of metallic components that will be fitted into several Airbus aircraft programs as part of assemblies produced by Premium AEROTEC.
Mahindra Aerospace’s deliverables under this contract will be in excess of a million parts per annum. The parts will be produced at the new Mahindra Aerostructures facility located at Narsapura, near Bengaluru, India. Deliveries to Premium AEROTEC’s facilities in Germany are scheduled to commence this year. Announcing the contract award during the 2015 Paris Air Show at Le Bourget, senior representatives of the Airbus and Mahindra groups mentioned that this contract is aligned with the Indian Government’s ‘Make in India’ initiative and validates the two Groups’ commitment to accelerate India’s participation in the global aerospace industry while simultaneously creating high-growth opportunities within India’s burgeoning aerospace and defense eco-system.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7551351-mahindra-airbus-make-in-india/
ConnXus, a supplier diversity technology platform, today announced that it has closed $5 million in Series “A” funding, led by Techstars Ventures, Serious Change L.P. and Impact America Fund.
“This round of funding will significantly accelerate ConnXus’ long-term impact on generating sustainable and diverse supply chains,” said Rod Robinson, CEO and founder of ConnXus. “To date we’ve raised $10 million in investments, including participation from Techstars Ventures, CincyTech, Serious Change L.P., Impact America Fund, and several private angel investors.”
ConnXus’ cloud-based, supplier diversity sustainability dashboards open the door for procurement, supplier diversity, and supply chain professionals to access a wealth of global supply chain analytics. Robinson believes Techstars and the other investors are the right investors for the company to disrupt and add imperative value to the $10-billion supply chain and procurement software market.
To view the multimedia release go to:
http://www.multivu.com/players/English/7834951-connxus-five-million-series-a/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Quadriplegic former IndyCar driver and current team owner Sam Schmidt completed the bottom half of the challenging, high-altitude Broadmoor Pikes Peak International Hill Climb yesterday in the Arrow Electronics, Inc. (NYSE:ARW) Semi-Autonomous Motorcar (SAM car).
Schmidt, who was paralyzed from the neck down in a crash during an IndyCar practice lap in 2000, is able to steer, accelerate and brake the modified 2016 Corvette Z06 SAM car using only his head. Sensors mounted on an Arrow-designed high-tech headset that Schmidt wears connect to infrared cameras mounted on the dashboard and detect his head-tilt motions to steer. A sip-and-puff device that Smith breathes into enables him to accelerate and brake.
The Prostate Cancer Foundation (PCF) announces the launch of the “Step Up for Blue” Campaign for Prostate Cancer Awareness Month. The campaign honors the millions of men and their families touched by prostate cancer worldwide.
“Step Up for Blue” focuses on elevating critical issues to inspire, energize, and accelerate actions that lead to greater awareness, new therapies, and fewer deaths from prostate cancer. It will run through the duration of September.
To view the multimedia release go to:
http://www.multivu.com/players/English/7729253-pcf-step-up-for-blue-prostate-cancer/
Breast cancer now represents one in four of all cancers in women worldwide and touches lives every day. While experiences with the disease may vary, the desire to defeat breast cancer is universal. This year, in honor of a shared vision for a world without this disease, The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign celebrates the power of global solidarity by encouraging people around the world to “Take Action Together to Defeat Breast Cancer.” The 2016 BCA Campaign invites women, men and families to draw inspiration from one another and unite in action on BCAcampaign.com and social media, while supporting lifesaving breast cancer research.
Over the past two decades, The Estée Lauder Companies’ BCA Campaign, launched by the late Evelyn H. Lauder, co-creator of the Pink Ribbon and founder of the Breast Cancer Research Foundation® (BCRF), has been a leading voice for breast cancer awareness around the world, igniting a global movement that has helped save millions of lives and fund innovative breast cancer research. Today, The BCA Campaign is active in more than 70 countries and has raised more than $65 million to support global research, education and medical services, with more than $50 million funding 200 BCRF medical research grants worldwide over the past 22 years. These funds help accelerate critical research across wide-ranging areas such as tumor biology, heredity and ethnicity, lifestyle and prevention, treatment, survivorship and metastasis. Around the world, The BCA Campaign partners with more than 60 breast cancer organizations focused on breast cancer research, education and medical services. This year, The BCA Campaign is committed to raising $6 million in support of its mission to defeat breast cancer through education and medical research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7935851-estee-lauder-bca-campaign-2016/
The American Cancer Society and the CVS Health Foundation today awarded grants to 20 U.S. colleges and universities as part of their Tobacco-Free Generation Campus Initiative (TFGCI), a $3.6 million multi-year program intended to accelerate and expand the adoption and implementation of 100 percent smoke- and tobacco-free campus policies. The announcement coincides this week with the American Cancer Society Great American Smokeout.
The Tobacco-Free Generation Campus Initiative is part of Be The First, CVS Health's five-year, $50 million initiative that supports education, advocacy, tobacco control, and healthy behavior programming to help deliver the nation’s first tobacco-free generation. CVS Health has set actionable and measurable goals for Be The First, including a doubling of the number of tobacco-free college and university campuses in the United States.
To view the multimedia release go to:
http://www.multivu.com/players/English/7963951-cvs-health-tobacco-free-campus/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
